國立虎尾科技大學 |

Immunotherapy of Sarcoma

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Immunotherapy of Sarcoma/ edited by Sandra P. D'Angelo, Seth M. Pollack.
其他作者:	D'Angelo, Sandra P.
面頁冊數:	VII, 152 p. 10 illus., 7 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Oncology . -
電子資源:	https://doi.org/10.1007/978-3-319-93530-0
ISBN:	9783319935300

Immunotherapy of Sarcoma
Immunotherapy of Sarcoma[electronic resource] /edited by Sandra P. D'Angelo, Seth M. Pollack. - 1st ed. 2019. - VII, 152 p. 10 illus., 7 illus. in color.online resource.

Part 1 The Immune Sarcoma Microenvironment -- 1 MDSC, Macrophage and CD47 -- 2 IDO and other inhibitory markers -- 3 Regulatory T cells -- 4 Radiation and sarcoma immunotherapy -- Part 2 Sarcoma Immunotherapeutics -- 5 Oncolytic Virus therapy -- 6 Vaccines -- 7 Immune Checkpoint Blockers -- 8 Adoptive T cell therapy.

This book describes recent progress in the development of immunotherapies for advanced sarcoma, paying special attention to the potential role of manipulations of the sarcoma tumor immune microenvironment in achieving durable remissions. Readers will find a thorough overview of the state of the art in tumor immunology and immunotherapy as they relate to sarcoma. Among the topics addressed are advances in vaccine therapy; the value of adoptive transfer of cytokine-induced natural killer cells; the development of adoptive T cell strategies; and the scope for use of checkpoint inhibitors in patients with sarcoma, mirroring the tremendous breakthroughs made in other malignancies. Detailed information is provided on laboratory and clinical research, with analysis of outcomes of recent trials and identification of key challenges. There is every reason to believe that more effective and less toxic therapies for metastatic sarcoma can be attained by deepening our understanding of cancer immunology and building on the advances in immunotherapy for other solid tumors. In this context, Immunotherapy of Sarcoma will be of high interest for all medical oncologists responsible for the treatment of sarcoma patients.

ISBN: 9783319935300

Standard No.: 10.1007/978-3-319-93530-0doiSubjects--Topical Terms:

1253469
Oncology .

LC Class. No.: RC254-282

Dewey Class. No.: 616.994

Immunotherapy of Sarcoma
LDR:02816nam a22003855i 4500 001 1009694
003 DE-He213
005 20200706022314.0
007 cr nn 008mamaa
008 210106s2019 gw | s |||| 0|eng d
020 $a 9783319935300 $9 978-3-319-93530-0
024 7 $a 10.1007/978-3-319-93530-0 $2 doi
035 $a 978-3-319-93530-0
050 4 $a RC254-282
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
245 1 0 $a Immunotherapy of Sarcoma $h [electronic resource] / $c edited by Sandra P. D'Angelo, Seth M. Pollack.
250 $a 1st ed. 2019.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a VII, 152 p. 10 illus., 7 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Part 1 The Immune Sarcoma Microenvironment -- 1 MDSC, Macrophage and CD47 -- 2 IDO and other inhibitory markers -- 3 Regulatory T cells -- 4 Radiation and sarcoma immunotherapy -- Part 2 Sarcoma Immunotherapeutics -- 5 Oncolytic Virus therapy -- 6 Vaccines -- 7 Immune Checkpoint Blockers -- 8 Adoptive T cell therapy.
520 $a This book describes recent progress in the development of immunotherapies for advanced sarcoma, paying special attention to the potential role of manipulations of the sarcoma tumor immune microenvironment in achieving durable remissions. Readers will find a thorough overview of the state of the art in tumor immunology and immunotherapy as they relate to sarcoma. Among the topics addressed are advances in vaccine therapy; the value of adoptive transfer of cytokine-induced natural killer cells; the development of adoptive T cell strategies; and the scope for use of checkpoint inhibitors in patients with sarcoma, mirroring the tremendous breakthroughs made in other malignancies. Detailed information is provided on laboratory and clinical research, with analysis of outcomes of recent trials and identification of key challenges. There is every reason to believe that more effective and less toxic therapies for metastatic sarcoma can be attained by deepening our understanding of cancer immunology and building on the advances in immunotherapy for other solid tumors. In this context, Immunotherapy of Sarcoma will be of high interest for all medical oncologists responsible for the treatment of sarcoma patients.
650 0 $a Oncology . $3 1253469
650 0 $a Immunology. $3 592892
650 1 4 $a Oncology. $3 593951
700 1 $a D'Angelo, Sandra P. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1303676
700 1 $a Pollack, Seth M. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1303677
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319935294
776 0 8 $i Printed edition: $z 9783319935317
856 4 0 $u https://doi.org/10.1007/978-3-319-93530-0
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)